The herein proposed Center of Excellence for Translational Research (CETR), which will be named the Antiviral Drug Discovery and Development Center (AD3C) has, at its center, the theme to develop new small molecule therapeutics for emerging and re-emerging viral infections. Translational research will focus on the inhibition of viral replication, especially viral polymerases. Progression pathways will includ target validation, high throughput screening to identify novel chemical scaffolds, and basic virologic research to prove and further probe the exact mechanism of action of identified lead molecules in viral replication. Medicinal chemistry and lead development activities will advance identified compounds down the drug discovery and development pathway, ultimately leading to preclinical evaluation of promising drug candidates for clinical evaluation. The AD3C has four interrelated research projects with a focus on flaviviruses, coronaviruses, alphaviruses and influenza. They will be supported in their efforts by three cores: an Administrative Core (Core A), a Screening Core (SC;Core B) and a Medicinal Chemistry and Lead Development Core (MCLDC;Core C). Organization and interaction between all projects and cores will be mediated out of the Administrative Core, with day to day AD3C operations led by the Core's personnel. An Executive Committee (EC) consisting of all project and core leaders will regularly review the projects'and cores'activities and productivity. Finally, an External Scientific Advisory Board (EAB) of distinguished scientists has been established to annually provide a high level evaluation of AD3C's progress and successes, and aid in refining the Center's activities and direction.

National Institute of Health (NIH)
National Institute of Allergy and Infectious Diseases (NIAID)
Research Program--Cooperative Agreements (U19)
Project #
Application #
Study Section
Special Emphasis Panel (ZAI1-LR-M (J1))
Program Officer
Beanan, Maureen J
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Alabama Birmingham
Schools of Medicine
United States
Zip Code
McCarthy, Mary K; Morrison, Thomas E (2017) Persistent RNA virus infections: do PAMPS drive chronic disease? Curr Opin Virol 23:8-15
Pryke, Kara M; Abraham, Jinu; Sali, Tina M et al. (2017) A Novel Agonist of the TRIF Pathway Induces a Cellular State Refractory to Replication of Zika, Chikungunya, and Dengue Viruses. MBio 8:
Sheahan, Timothy P; Sims, Amy C; Graham, Rachel L et al. (2017) Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses. Sci Transl Med 9:
Haese, Nicole N; Broeckel, Rebecca M; Hawman, David W et al. (2016) Animal Models of Chikungunya Virus Infection and Disease. J Infect Dis 214:S482-S487
McCarthy, Mary K; Morrison, Thomas E (2016) Chronic chikungunya virus musculoskeletal disease: what are the underlying mechanisms? Future Microbiol 11:331-4
Everts, Maaike; Suto, Mark J; Painter, George R et al. (2016) Consortia's critical role in developing medical countermeasures for re-emerging viral infections: a USA perspective. Future Virol 11:187-195
Rasmussen, Lynn; White, E Lucile; Bostwick, James R (2016) Acoustic Droplet Ejection Applications for High-Throughput Screening of Infectious Agents. J Lab Autom 21:188-97
Morrison, Clayton R; Plante, Kenneth S; Heise, Mark T (2016) Chikungunya Virus: Current Perspectives on a Reemerging Virus. Microbiol Spectr 4:
Mounce, Bryan C; Cesaro, Teresa; Moratorio, Gonzalo et al. (2016) Inhibition of Polyamine Biosynthesis Is a Broad-Spectrum Strategy against RNA Viruses. J Virol 90:9683-9692
Mainou, Bernardo A; Ashbrook, Alison W; Smith, Everett Clinton et al. (2015) Serotonin Receptor Agonist 5-Nonyloxytryptamine Alters the Kinetics of Reovirus Cell Entry. J Virol 89:8701-12

Showing the most recent 10 out of 18 publications